AEG tissues; matching healthy gastric mucosal tissues; adjacent normal mucosal tissues; noncancerous gastric mucosal tissues; paraffin-embedded AEG tissues; frozen tissues
HGC-27; AGS; SK-GT-4; GES-1; 293 T
cell line-derived xenograft
ceRNA regulation (promotes); proliferation (promotes); migration (promotes); invasion (promotes); apoptosis (inhibits); cell cycle (promotes); EMT (promotes); metastasis (promotes)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; RNA-seq; FISH / smFISH; ISH (In Situ Hybridization); Clinical Sample Validation; Luciferase Reporter Assay; Transfection; CCK8; Annexin V/PI Flow Cytometry; Cell Cycle Assay; Transwell Assay; Wound Healing Assay; In Vivo Animal Model; IHC (Immunohistochemistry); Western Blot; Survival Analysis; ROC Analysis; Bioinformatics Analysis
circRNA0007766 upregulation is correlated with lymph node involvement, poor prognosis, short overall survival, and may serve as a specific and sensitive diagnostic biomarker and potential novel AEG biomarker.
circRNA0007766 is a human ERBB2-derived circRNA that is significantly upregulated in AEG tissues and cell lines. It promotes AEG proliferation, migration, invasion, tumorigenesis, cell cycle progression and EMT-related changes while reducing apoptosis, mainly through a ceRNA mechanism in which it sponges miR-34c-5p to upregulate cyclin D1. Clinically, high circRNA0007766 expression is associated with lymph node metastasis, poor prognosis and shorter overall survival, suggesting diagnostic and prognostic biomarker potential.
0.8648
CircRNA0007766 accelerates cancer progression via miR-34c-5p/cyclin D1 axis in adenocarcinoma of the esophagogastric junction (AEG).
combined biological and clinical study